| Autor: |
Khan S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., LeBlanc R; Hȏspital Maisonneuve-Rosemont, Montreal, Canada., Gyger M; Jewish General Hospital, Montreal, Canada., White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Canada., Kaufman J; Winship Cancer Institute Emory University School of Medicine, Atlanta, GA, USA., Jazubowiak A; Division of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA., Gul E; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Paul H; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Le LW; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada., Lau A; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada., Li Z; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Trudel S; Princess Margaret Cancer Centre Ontario Cancer Institute, Toronto, Canada. |
| Abstrakt: |
We report results of a phase-1 study evaluating the safety and anti-cancer activity of the small molecule insulin-like growth factor-1 receptor (IGF-1R) inhibitor, linsitinib combined with bortezomib, and dexamethasone in relapsed/refractory multiple myeloma. Nineteen patients were enrolled across four dose-escalation cohorts (75-150 mg bid). The maximum tolerated dose of linsitinib was 125 mg. The most frequent Grade 3/4 AEs occurring in ≥10% of patients were thrombocytopenia (53%), bone pain (26%), neutropenia (21%), diarrhea (14%), anemia (14%), rash (10%), and lung infection (10%). Study discontinuation due to treatment-related AEs was low (16%). Across all cohorts the ORR was 61% (95% CI: 28.9-75.6%). Three partial response or greater and one stable disease were observed in proteasome inhibitor (PI) refractory patients ( n = 5). Median PFS was 7.1 months (95% CI: 3.6-NA). Linsitinib plus bortezomib and dexamethasone demonstrate a manageable safety profile while the clinical benefit particularly in PI refractory patients warrants further exploration. |
